Web Exclusives

The Centers for Medicare & Medicaid Services (CMS) has broadened access to Medicare telehealth services so that beneficiaries can receive a wider range of services from their physicians without having to travel to a healthcare facility. Clinicians can bill immediately for services starting March 6, 2020. Read More ›

Medically integrated dispensing models enhance oral oncology drug education and improve compliance and patient monitoring. Read More ›

New model aims to ease transition from fee-for-service to value-based cancer care delivery using an oncology medical home framework and performance-based reimbursement that includes monthly care management payments. Read More ›

Incident cases of ovarian cancer differed little between ever users and never users of powder with no dose-response relationship. Read More ›

Pivotal phase 3 data demonstrated treatment with luspatercept resulted in statistically significant increased red blood cell transfusion independence compared with placebo. Read More ›

Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately. Read More ›

Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level. Read More ›

The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes. Read More ›

Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020. Read More ›

On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020. Read More ›